Molecular Partners Announces Newly Nominated Board Members for Upcoming Annual Meeting
Zurich-Schlieren, Switzerland, February 20, 2020. Molecular Partners AG (SIX: MOLN), a clinicalstage biotech company that is developing a new class of drugs known as DARPin® therapies, today
announced the nomination of three new board members, proposed for election at the 2020 Annual
General Meeting on April 29, 2020.
Nominees are as follows:
• Sandip Kapadia, Chief Financial Officer (CFO) of Intercept Pharmaceuticals
• Michael Vasconcelles, M.D., Chief Medical Officer (CMO) of Flatiron Health
• Vito J. Palombella, Ph.D., Chief Scientific Officer (CSO) of Surface Oncology
These nominees have been selected to coincide with the transition of three current members of the
board, Goran Ando, William Lee and Petri Vainio. Each of these board members has dutifully served
on the Molecular Partners board for 10 years or more and will not stand for re-election. The board’s
new nominees are veteran U.S. biotech executives and experts in their respective fields, each of
which deeply aligns with the current and future growth strategy of Molecular Partners and
complements well with the rest of the board’s backgrounds and skills. Their collective experience in
finance, business development, innovative clinical trial design, and early-stage drug discovery will be
critical to Molecular Partners’ ongoing growth into a fully integrated oncology company with
multiple assets in clinical development.